Long-term pharmacotherapy for obesity and overweight
Cochrane Database of Systematic ReviewsPublished 20 October 2003Open access
Raj Padwal, Diana Rucker, Stephanie K Li, Cíntia Chaves Curioni, David C.W. Lau
Citations379
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Average weight losses with current anti-obesity agents appear modest but may be of clinical benefit, and better studies designed to examine mortality and cardiovascular morbidity are required to fully evaluate any potential benefit of such agents.
Abstract
Studies evaluating the long-term efficacy of anti-obesity agents are limited to orlistat and sibutramine. Both drugs appear modestly effective in promoting weight loss; however, interpretation is limited by high attrition rates. Longer and more methodologically rigorous studies of anti-obesity drugs that are powered to examine endpoints such as mortality and cardiovascular morbidity are required to fully evaluate any potential benefit of such agents.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
BMJBias in meta-analysis detected by a simple, graphical test
56,268 Citations1997Matthias Egger, George Davey Smith +2 more
Funnel plots, plots of the trials' effect estimates against sample size, are skewed and asymmetrical in the presence of publication bias and other biases Funnel plot asymmetry, measured by regression analysis, predicts discordance of results when meta-analyses are compared with single large trials.
New England Journal of MedicineReduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin
19,026 Citations2002Diabetes Prevention Program Research Group
Lifestyle changes and treatment with metformin both reduced the incidence of diabetes in persons at high risk and the lifestyle intervention was more effective than meetformin.
PubMedObesity: preventing and managing the global epidemic. Report of a WHO consultation.
13,241 Citations2000
The fundamental causes of the obesity epidemic are sedentary lifestyles and high-fat energy-dense diets, both resulting from the profound changes taking place in society and the behavioural patterns of communities as a consequence of increased urbanization and industrialization and the disappearance of traditional lifestyles.
New England Journal of MedicinePrevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance
10,818 Citations2001Jaakko Tuomilehto, Jaana Lindström +17 more
Type 2 diabetes can be prevented by changes in the lifestyles of high-risk subjects by means of individualized counseling aimed at reducing weight, total intake of fat, and intake of saturated fat and increasing intake of fiber and physical activity.
Obesity Facts‘Small Changes' to Diet and Physical Activity Behaviors for Weight Management
9,509 Citations2013Andrew P. Hills, Nuala M. Byrne +2 more
A case for the use of small and incremental changes in diet and physical activity for improved weight management in the context of a toxic obesogenic environment is presented.
Obesity FactsThe Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function
8,483 Citations2017Gijs H. Goossens
Detailed metabolic phenotyping of obese persons will be invaluable in understanding the pathophysiology of metabolic disturbances, and is needed to identify high-risk individuals or subgroups, thereby paving the way for optimization of prevention and treatment strategies to combat cardiometabolic diseases.
JAMAPrevalence and Trends in Obesity Among US Adults, 1999-2000
6,205 Citations2002Katherine M. Flegal
The increases in the prevalences of obesity and overweight previously observed continued in 1999-2000, and increases occurred for both men and women in all age groups and for non-Hispanic whites, non- Hispanic blacks, and Mexican Americans.
The LancetImproving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
4,808 Citations1999David Moher, Fadi Hammal +4 more
This report hopes this report will generate further thought about ways to improve the quality of reports of meta-analyses of RCTs and that interested readers, reviewers, researchers, and editors will use the QUOROM statement and generate ideas for its improvement.
NatureObesity as a medical problem
4,787 Citations2000Peter Kopelman
The global epidemic of obesity results from a combination of genetic susceptibility, increased availability of high-energy foods and decreased requirement for physical activity in modern society, and should be regarded as an epidemic that threatens global well being.
New England Journal of MedicineLifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery
4,405 Citations2004Lars Sjöström, Anna‐Karin Lindroos +10 more
As compared with conventional therapy, bariatric surgery appears to be a viable option for the treatment of severe obesity, resulting in long-term weight loss, improved lifestyle, and, except for hypercholesterolemia, amelioration in risk factors that were elevated at baseline.
JAMAPrevalence and Trends in Overweight Among US Children and Adolescents, 1999-2000
4,096 Citations2002Cynthia L. Ogden
The prevalence of overweight among children in the United States is continuing to increase, especially among Mexican-American and non-Hispanic black adolescents.
New England Journal of MedicineBody-Mass Index and Mortality in a Prospective Cohort of U.S. Adults
3,664 Citations1999Eugenia E. Calle, Michael J. Thun +3 more
New England Journal of MedicineObesity and the Risk of Heart Failure
2,956 Citations2002Satish Kenchaiah, Jane C. Evans +6 more
In this large, community-based sample, increased body-mass index was associated with an increased risk of heart failure and strategies to promote optimal body weight may reduce the population burden ofheart failure.
The LancetObesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study
2,897 Citations2005Salim Yusuf, Steven Hawken +13 more
Redefinition of obesity based on waist-to-hip ratio instead of BMI increases the estimate of myocardial infarction attributable to obesity in most ethnic groups.
The LancetAcarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
2,533 Citations2002Jean‐Louis Chiasson, Robert G. Josse +4 more
Acarbose could be used, either as an alternative or in addition to changes in lifestyle, to delay development of type 2 diabetes in patients with impaired glucose tolerance.
Journal of Clinical EpidemiologyThe Delphi List
2,352 Citations1998Arianne P. Verhagen, Henrica C. W. de Vet +5 more
The aim of this study was to obtain consensus among experts about a set of generic core items for quality assessment of randomized clinical trials (RCTs) and the final criteria list (the Delphi list) was satisfactory to all participants.
BMJPharmaceutical industry sponsorship and research outcome and quality: systematic review
2,163 Citations2003Joel Lexchin, Lisa A Bero +2 more
Investigating whether funding of drug studies by the pharmaceutical industry is associated with outcomes that are favourable to the funder and whether the methods of trials funded by pharmaceutical companies differ from the methods in trials with other sources of support found systematic bias favours products which are made by the company funding the research.
BMJWhat is meant by intention to treat analysis? Survey of published randomised controlled trials
2,130 Citations1999S. Hollis, Fiona Campbell
Assessment of reports of randomised controlled trials published in 1997 found that intention to treat was used, but handling of deviations from randomised allocation varied widely and methods used to deal with this were generally inadequate, potentially leading to bias.
International Journal of ObesityA within-trial cost-effectiveness analysis of primary care referral to a commercial provider for weight loss treatment, relative to standard care—an international randomised controlled trial
2,116 Citations2012Nicholas R. Fuller, Stephen Colagiuri +10 more
This study indicates that it is cost effective for general practitioners to refer overweight and obese patients to a CP, which may be better value than expending public funds on GP visits to manage this problem.
Annals of Internal MedicineWeight Gain as a Risk Factor for Clinical Diabetes Mellitus in Women
2,059 Citations1995Graham A. Colditz, Walter C. Willett +2 more
The relations between change in adult weight and the risk for noninsulin-dependent diabetes mellitus among women during 14 years of follow-up were quantified.
New England Journal of MedicineChanges in Energy Expenditure Resulting from Altered Body Weight
1,999 Citations1995Rudolph L. Leibel, Michael Rosenbaum +1 more
Maintenance of a reduced or elevated body weight is associated with compensatory changes in energy expenditure, which oppose the maintenance of a body weight that is different from the usual weight, which may account for the poor long-term efficacy of treatments for obesity.
New England Journal of MedicineBody Weight and Mortality among Women
1,989 Citations1995JoAnn E. Manson, Walter C. Willett +6 more
JAMATelevision Watching and Other Sedentary Behaviors in Relation to Risk of Obesity and Type 2 Diabetes Mellitus in Women
1,905 Citations2003Frank B. Hu, Tricia Y. Li +3 more
Independent of exercise levels, sedentary behaviors, especially TV watching, were associated with significantly elevated risk of obesity and type 2 diabetes, whereas even light to moderate activity was associated with substantially lower risk.
Diabetes CareXENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
1,902 Citations2004Jarl Torgerson, Jonathan Hauptman +2 more
Compared with lifestyle changes alone, orlistat plus lifestyle changes resulted in a greater reduction in the incidence of type 2 diabetes over 4 years and produced greater weight loss in a clinically representative obese population.
The LancetEffect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
1,715 Citations2006‡
Rosiglitazone at 8 mg daily for 3 years substantially reduces incident type 2 diabetes and increases the likelihood of regression to normoglycaemia in adults with impaired fasting glucose or impaired glucose tolerance, or both.
Archives of Internal MedicineImpact of Overweight on the Risk of Developing Common Chronic Diseases During a 10-Year Period
1,673 Citations2001Alison E. Field, Eugenie Coakley +6 more
The dose-response relationship between BMI and the risk of developing chronic diseases was evident even among adults in the upper half of the healthy weight range, suggesting that adults should try to maintain a BMI between 18.5 and 21.9 to minimize their risk of disease.
New England Journal of MedicineValvular Heart Disease Associated with Fenfluramine–Phentermine
1,635 Citations1997Heidi M. Connolly, Jack L. Crary +5 more
Concerns are raised that fenfluramine-phentermine therapy may be associated with valvular heart disease, which is arouse concern about serious potential adverse effects, including pulmonary hypertension and valvULAR heart disease.
New England Journal of MedicineThe Effect of Age on the Association between Body-Mass Index and Mortality
1,628 Citations1998June Stevens, Jianwen Cai +4 more
Excess body weight increases the risk of death from any cause and from cardiovascular disease in adults between 30 and 74 years of age and the relative risk associated with greater body weight is higher among younger subjects.
The LancetEffects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
1,487 Citations2005Luc F. Van Gaal, Aila Rissanen +3 more
CB1 blockade with rimonabant 20 mg, combined with a hypocaloric diet over 1 year, promoted significant decrease of bodyweight and waist circumference, and improvement in cardiovascular risk factors.
New England Journal of MedicineEffects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia
1,389 Citations2005Jean‐Pierre Després, Alain Golay +1 more
DiabetesPreservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women
1,343 Citations2002Thomas A. Buchanan, Anny H. Xiang +9 more
Protection from diabetes in the troglitazone group was closely related to the degree of reduction in endogenous insulin requirements 3 months after randomization and persisted 8 months after study medications were stopped, and was associated with preservation of beta-cell compensation for insulin resistance.
JAMAEffect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients
1,215 Citations2006F. Xavier Pi‐Sunyer, Louis J. Aronne +4 more
Treatment with 20 mg/d of rimonabant plus diet for 2 years promoted modest but sustained reductions in weight and waist circumference and favorable changes in cardiometabolic risk factors, however, the trial was limited by a high drop-out rate and longer-term effects of the drug require further study.
The LancetRandomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
1,203 Citations1998Lars Sjöström, Aila Rissanen +5 more
Orlistat taken with an appropriate diet promotes clinically significant weight loss and reduces weight regain in obese patients over a 2-year period and the use of orlistat beyond 2 years needs careful monitoring with respect to efficacy and adverse events.
New England Journal of MedicineAppetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension
1,161 Citations1996Lucien Abenhaim, Yola Moride +10 more
The use of anorexic drugs was associated with the development of primary pulmonary hypertension and active surveillance for this disease should be considered, particularly since their use is expected to increase in the near future.
Canadian Medical Association Journal2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]
1,158 Citations2007David C.W. Lau, James D. Douketis +4 more
Over the last 20 years, obesity has become the most prevalent nutritional problem in the world, eclipsing undernutrition and infectious disease.
JAMAWeight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat
937 Citations1999Michael Davidson, Jonathan Hauptman +9 more
Two-year treatment with orlistat plus diet significantly promotes weight loss, lessens weight regain, and improves some obesity-related disease risk factors.
Archives of Internal MedicineExecutive Summary of the Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults
927 Citations1998Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults
PubMedBeneficial health effects of modest weight loss.
920 Citations1992D J Goldstein
In conclusion, a large proportion of obese individuals with NIDDM, hypertension, and hyperlipidemia experienced positive health benefits with modest weight loss, and even a small amount of weight loss appears to benefit a substantial subset of obese patients.
American Journal of EpidemiologyBody Size and Fat Distribution as Predictors of Coronary Heart Disease among Middle-aged and Older US Men
838 Citations1995Eric B. Rimm, Meir J. Stampfer +5 more
For younger men, obesity, independent offat distribution, is a strong risk factor for coronary heart disease, and for older men, measures of fat distribution may be better than body mass index at predicting risk of coronary disease.
The LancetEffect of sibutramine on weight maintenance after weight loss: a randomised trial
816 Citations2000W. P. T. James, Arne Astrup +6 more
Changes in concentrations of HDL cholesterol, VLDL cholesterol, and triglyceride, but not LDL cholesterol, exceed those expected either from weight loss alone or when induced by other selective therapies for low concentrations of LDL cholesterol relating to coronary heart disease.
New England Journal of MedicineRandomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity
788 Citations2005Thomas A. Wadden, Robert I. Berkowitz +8 more
The combination of medication and group lifestyle modification resulted in more weight loss than either medication or lifestyle modification alone and underscores the importance of prescribing weight-loss medications in combination with, rather than in lieu of, lifestyle modification.
Controlled Clinical TrialsLook AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes
775 Citations2003Donna H. Ryan
The Look AHEAD clinical trial is to assess the long-term effects of an intensive weight loss program delivered over 4 years in overweight and obese individuals with type 2 diabetes and is designed to provide a 0.90 probability of detecting an 18% difference in major CVD event rates between the two groups.
Annals of Internal MedicineMeta-Analysis: Pharmacologic Treatment of Obesity
773 Citations2005Zhaoping Li, Margaret Maglione +9 more
This review of 79 clinical trials involving diet plus the obesity drugs sibutramine, orlistat, fluoxetine, sertraline, bupropion, topiramate, or zonisamide shows that these medications can lead to modest weight reductions of approximately 5 kg or less at 1 year.
The LancetDrug treatments for obesity: orlistat, sibutramine, and rimonabant
744 Citations2007Raj Padwal, Sumit R. Majumdar
As new drugs are developed, it is suggested that the assessment processes should include both surrogate endpoints and clinical outcomes, so that patients and their physicians can be confident that the putative benefits of such drugs outweigh their risks and costs.
The LancetEfficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
734 Citations2006André Scheen, Nick Finer +3 more
20 mg/day rimonabant, in combination with diet and exercise, can produce a clinically meaningful reduction in bodyweight and improve HbA1c and a number of cardiovascular and metabolic risk factors in overweight or obese patients with type 2 diabetes inadequately controlled by metformin or sulphonylureas.
Diabetes CareRole of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study
657 Citations1998Priscilla Hollander, Steven C. Elbein +13 more
Orlistat is an effective treatment modality in obese patients with type 2 diabetes with respect to clinically meaningful weight loss and maintenance of weight loss, improved glycemic control, and improved lipid profile.
JAMAA Prospective Study of Body Mass Index, Weight Change, and Risk of Stroke in Women
598 Citations1997Kathryn M. Rexrode
Obesity and weight gain in women are important risk factors for ischemic and total stroke but not hemorrhagic stroke, according to prospective data from the Nurses' Health Study, which examined the associations of body mass index (BMI) and weight change with risk of stroke in women.
Diabetes CareIntentional weight loss and mortality among overweight individuals with diabetes.
565 Citations2000David F. Williamson, Theodore J. Thompson +4 more
Intentional weight loss was associated with substantial reductions in mortality in this observational study of overweight individuals with diabetes.
ACC Current Journal ReviewAppetite-suppressant drugs and the risk of primary pulmonary hypertension
563 Citations1997
American Journal of EpidemiologyProspective Study of Intentional Weight Loss and Mortality in Never-Smoking Overweight US White Women Aged 40–64 Years
530 Citations1995David F. Williamson, Elsie R. Pamuk +4 more
The association between intentional weight loss and longevity in middle-aged overweight women appears to depend on their health status, whereas among women with no preexisting illness, the association is equivocal.
Obesity ResearchEffect of Degree of Weight Loss on Health Benefits
506 Citations1995George L. Blackburn
The effect of degree of weight loss on specific disease states and risk factors is reviewed and the impact of ethnic background, fat distribution, age, and mode of weight Loss on outcome is discussed.
Obesity ResearchWeight Loss, Weight Maintenance, and Improved Cardiovascular Risk Factors after 2 Years Treatment with Orlistat for Obesity
479 Citations2000Stephan Rössner, Lars Sjöström +4 more
Orlistat administered for 2 years promotes weight loss and minimizes weight regain, and additionally, orlistat therapy improves lipid profile, blood pressure, and quality of life.
Annals of Internal MedicineTreatment of Obesity by Moderate and Severe Caloric Restriction: Results of Clinical Research Trials
473 Citations1993Thomas A. Wadden
The effectiveness of moderate caloric restriction was assessed by examining all studies published in four behavioral journals in 1974 and 1978 and from 1984 to 1990 and all controlled studies of severe caloric restriction that included follow-up data were reviewed.
International Journal of ObesityA comparison of body mass index, waist–hip ratio and waist circumference as predictors of all-cause mortality among the elderly: the Rotterdam study
439 Citations2001TLS Visscher, Jacob C. Seidell +4 more
Among never smoking elderly men waist circumference may have more potential for detecting overweight than the BMI, according to a population-based cohort study.
NatureMedicinal strategies in the treatment of obesity
436 Citations2000George A. Bray, Louis A. Tartaglia
For a drug to have significant impact on body weight it must ultimately reduce energy intake, increase energy expenditure, or both.
Cochrane Database of Systematic ReviewsLong-term pharmacotherapy for obesity and overweight
379 Citations2003Raj Padwal, Diana Rucker +3 more
Average weight losses with current anti-obesity agents appear modest but may be of clinical benefit, and better studies designed to examine mortality and cardiovascular morbidity are required to fully evaluate any potential benefit of such agents.
Archives of Family MedicineOrlistat in the Long-term Treatment of Obesity in Primary Care Settings
370 Citations2000Jonathan Hauptman
This long-term study indicates that orlistat is an effective adjunct to dietary intervention in the treatment of obesity in primary care settings and was well tolerated, although treatment resulted in a higher incidence of gastrointestinal events.
Archives of Internal MedicineEffects of Weight Loss With Orlistat on Glucose Tolerance and Progression to Type 2 Diabetes in Obese Adults
358 Citations2000Steven B. Heymsfield, Karen R. Segal +6 more
The addition of orlistat to a conventional weight loss regimen significantly improved oral glucoseolerance and diminished the rate of progression to the development of impaired glucose tolerance and type 2 diabetes.
Cochrane Database of Systematic ReviewsLong-term non-pharmacological weight loss interventions for adults with type 2 diabetes mellitus
350 Citations2005Susan L. Norris, Xuanping Zhang +5 more
The American Journal of MedicineLong-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine
348 Citations1999M Apfelbaum, P Vague +4 more
Following a very-low-calorie diet, sibutramine is effective in maintaining and improving weight loss for up to 1 year.
PubMedThe cost of obesity in Canada.
326 Citations1999C. Laird Birmingham, Joël Müller +3 more
The total direct cost of obesity in Canada in 1997 was estimated to be over $1.8 billion, and it is anticipated that the prevention and treatment of obesity will have major positive effects on the overall cost of health care.
International Journal of ObesityOne-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor
321 Citations2000Nick Finer, W. P. T. James +3 more
Orlistat was well tolerated and offered a promising new approach to the long-term management of obesity, and produced greater and more frequent significant weight loss than placebo during 1 y of treatment.
Diabetes CareClinical Efficacy of Orlistat Therapy in Overweight and Obese Patients With Insulin-Treated Type 2 Diabetes
312 Citations2002David E. Kelley, George A. Bray +5 more
Orlistat therapy produces clinically significant weight loss, with improvements in glycemic control and cardiovascular disease risk factors, in overweight or obese patients with type 2 diabetes who have suboptimal metabolic control with insulin therapy.
PubMedBenefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial.
305 Citations2001Thomas A. Wadden, Robert I. Berkowitz +3 more
The addition of group lifestyle modification to the pharmacologic management of obesity significantly improved weight loss and patients' satisfaction with treatment outcome.
International Journal of ObesityPharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials
298 Citations2002C. Keith Haddock, WSC Poston +3 more
This article provides the first comprehensive meta-analysis of randomized clinical trials of medications for obesity, and no drug, or class of drugs, demonstrated clear superiority as an obesity medication.
American Journal of Clinical NutritionOrlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study
290 Citations1999James O. Hill, Jonathan Hauptman +6 more
The use of orlistat during periods of attempted weight maintenance minimizes weight readjustment and facilitates long-term improvement in obesity-related disease risk factors.
Diabetes CareEffect of Orlistat in Overweight and Obese Patients With Type 2 Diabetes Treated With Metformin
285 Citations2002John M. Miles, Lawrence A. Leiter +7 more
Orlistat is a useful adjunctive treatment for producing weight loss and improving glycemic control, serum lipid levels, and blood pressure in obese patients with type 2 diabetes who are being treated with metformin.
JAMALong-term Weight Loss With Sibutramine
274 Citations2001Alfred Wirth, Jessica Krause
Sibutramine, administered for 48 weeks to a typically obese population, results in clinically relevant weight loss compared with placebo, andTherapeutic equivalence of the 2 active treatments could be shown.
Annals of Internal MedicineLong-Term Effects of Change in Body Weight on All-Cause Mortality: A Review
267 Citations1993Reubin Andres, D C Muller +1 more
New England Journal of MedicineThe Prevalence of Cardiac Valvular Insufficiency Assessed by Transthoracic Echocardiography in Obese Patients Treated with Appetite-Suppressant Drugs
266 Citations1998Mehmood Khan, Charles A. Herzog +6 more
Obese patients who took fen fluramine and phentermine, dexfenfluramine alone, or dexfanfluramines and phen termine for various periods had a significantly higher prevalence of cardiac valvular insufficiency than a matched group of control subjects.
New England Journal of MedicineA Population-Based Study of Appetite-Suppressant Drugs and the Risk of Cardiac-Valve Regurgitation
262 Citations1998Hershel Jick, Catherine Vasilakis +4 more
The use of fenfluramine or dexfen fluramine, particularly for four months or longer, is associated with an increased risk of newly diagnosed cardiac-valve disorders, particularly aortic regurgitation.
Archives of Internal MedicineThe Efficacy and Safety of Sibutramine for Weight Loss
253 Citations2004David Arterburn, Paul K. Crane +1 more
Sibutramine is effective in promoting weight loss and is associated with both positive and negative changes in cardiovascular and metabolic risk factors, and there is insufficient evidence to accurately determine the long-term risk-benefit profile for sibutamine.
Archives of Internal MedicineEfficacy and Safety of Sibutramine in Obese White and African American Patients With Hypertension
247 Citations2000F. Gilbert McMahon, Ken Fujioka +6 more
In obese patients with controlled hypertension, sibutramine was an effective and well-tolerated treatment for weight loss and maintenance and was associated with significant improvements in serum levels of triglycerides, HDL-C, glucose, and uric acid.
International Journal of ObesityWeight loss increases and fat loss decreases all-cause mortality rate: results from two independent cohort studies
233 Citations1999David B. Allison, Raffaella Zannolli +6 more
Among individuals that are not severely obese, weight loss is associated with increased mortality rate and fat loss with decreased mortality rate.
New England Journal of MedicineAn Assessment of Heart-Valve Abnormalities in Obese Patients Taking Dexfenfluramine, Sustained-Release Dexfenfluramine, or Placebo
225 Citations1998Neil J. Weissman, John F. Tighe +2 more
The increased prevalence of aortic and mitral regurgitation in patients treated with dexfenfluramine was small, and the degree ofregurgitation was usually classified as physiologic, trace, or mild.
Journal of Internal MedicineThe effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study
205 Citations2000Folke Lindgärde
The effect of orlistat on body weight and coronary heart disease risk profile in obese patients in the Swedish Multimorbidity Study is illustrated.
Diabetes CareType II Diabetic Subjects Lose Less Weight Than Their Overweight Nondiabetic Spouses
192 Citations1987Rena R. Wing, Marsha D. Marcus +2 more
Nondiabetic subjects reduced their intake significantly more than diabetics, suggesting that differences in dietary adherence were responsible for the differences in weight loss.
Diabetes CareA Randomized Trial of Sibutramine in the Management of Obese Type 2 Diabetic Patients Treated With Metformin
167 Citations2003Steven McNulty, Ehud Ur +1 more
Sibutramine can be an effective adjunct to metformin treatment in selected obese type 2 diabetic subjects and improves metabolic control in individuals who lose weight.
Annals of Internal MedicineMethods for Voluntary Weight Loss and Control
167 Citations1993NIH Technology Assessment Conference Panel
To evaluate methods for voluntary weight loss and control, the National Institutes of Health Nutrition Coordinating Committee and the Office of Medical Applications of Research held a technology assessment conference and agreed on answers to the following questions.
Diabetes CareA Systematic Review of Drug Therapy to Delay or Prevent Type 2 Diabetes
163 Citations2005Raj Padwal, Sumit R. Majumdar +3 more
No single agent can be definitively recommended for diabetes prevention and future studies should be designed with diabetes incidence as the primary outcome and should be of sufficient duration to differentiate between genuine diabetes prevention as opposed to simple delay or masking of this condition.
PubMedThe impact of obesity on health status: some implications for health care costs.
161 Citations1995Jacob C. Seidell
Obesity (defined as a body mass index > 30 kg/m2) is common in middle-aged Europeans and is notably high in women from Mediterranean and Eastern European countries.
Annals of PharmacotherapySibutramine: A Serotonin–Norepinephrine Reuptake-Inhibitor for the Treatment of Obesity
157 Citations1999Carla A. Luque, Jose A Rey
Based on anorectic efficacy data, sibutramine, a serotonin–norepinephrine reuptake-inhibitor, is a viable therapeutic option for the treatment of obesity.
American Journal of EpidemiologyProspective Study of Intentionality of Weight Loss and Mortality in Older Women: The lowa Women's Health Study
156 Citations1999Simone A. French, Aaron R. Folsom +2 more
The findings suggest that the association between weight loss and increased mortality risk observed in epidemiologic studies may be due to unintentional weight loss that reflects existing disease and not due to intentional weight loss.
PubMedRandomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.
151 Citations2001Ian Smith, Michael A. Goulder
Sibutramine 10 mg or 15 mg once daily given with dietary advice produces and maintains statistically and clinically significantly greater weight loss than dietary advice alone (placebo) throughout a 12-month treatment period, and is safe and well tolerated.
Diabetes Obesity and MetabolismThe effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo‐controlled trial
148 Citations2002M Hanefeld, G. Sachse
The aim of this study is to assess the long‐term effects of orlistat on body weight, glycaemic control and cardiovascular risk factors in overweight patients with type 2 diabetes.
Cochrane Database of Systematic ReviewsRimonabant for overweight or obesity
140 Citations2006Cíntia Chaves Curioni, Charles André
The use of rimonabant after one year produces modest weight loss of approximately 5%.
DrugsOrlistat
129 Citations1998Wendy McNeely, Paul Benfield
Obese patients who were maintained on a hypocaloric diet and who received orlistat 360 mg/day for 12 weeks lost a significantly greater percentage of bodyweight than placebo recipients, in 1- and 2-year studies.
Health Technology AssessmentA rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity
117 Citations2001Susan O’Meara, Rob Riemsma +3 more
Most of the trials showed greater weight loss and better weight maintenance with orlistat compared to placebo at all endpoints, and most trials showed significant improvement in at least some lipid concentration parameters, and, in three RCTs, or listat produced statistically significant reductions in blood pressure relative to placebo.
Canadian Medical Association JournalSynopsis of the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children
116 Citations2007David C.W. Lau
The 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children have been prepared as a supplement to this issue of CMAJ.
PubMedA one-year trial to assess the value of orlistat in the management of obesity.
116 Citations1997W. P. T. James, Alison Avenell +2 more
This preliminary analysis suggests that orlistat, when used with a health-promoting low-fat and moderately energy-restricted diet, confers advantages in the long-term management of obesity.
International Journal of ObesityLong-term persistence with orlistat and sibutramine in a population-based cohort
113 Citations2007Raj Padwal, Abbas Kezouh +2 more
This population-based, retrospective cohort analysis demonstrated very poor long-term persistence rates with orlistat and sibutramine and discontinuation rates that were much higher than those reported in clinical trials.
Cochrane Database of Systematic ReviewsPharmacotherapy for weight loss in adults with type 2 diabetes mellitus
113 Citations2005Susan L. Norris, Xuanping Zhang +4 more
Fluoxetine, orlistat, and sibutramine can achieve statistically significant weight loss over 12 to 57 weeks, but the magnitude of weight loss is modest, however, and the long-term health benefits remain unclear.
Diabetic MedicineA randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin
112 Citations2005Christian Berne, the Orlistat Swedish Type 2 diabetes Study Group
The objective is to assess the effects of orlistat vs. placebo, in combination with a weight management programme, on weight loss and metabolic control in obese patients with Type 2 diabetes.
Journal of Human HypertensionSibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors
110 Citations2002F. Gilbert McMahon, Samuel Weinstein +4 more
In obese patients whose hypertension is well controlled at the outset with an ACE inhibitor, with or without concomitant thiazide diuretic therapy, sibutramine safely and effectively achieves weight loss without compromising good BP control, this study indicates.
Journal of HypertensionTreatment with orlistat reduces cardiovascular risk in obese patients
109 Citations1998James H. Zavoral
Orlistat was well tolerated and had a similar safety profile to placebo, and orlistat-treated patients had significantly greater improvements in several lipid parameters including total cholesterol, low-density lipoproteincholesterol, triglycerides, and apolipoprotein B.
International Journal of Clinical PracticeRANDOMISED TRIAL OF THE EFFECT OF ORLISTAT ON BODY WEIGHT AND CARDIOVASCULAR DISEASE RISK PROFILE IN OBESE PATIENTS: UK MULTIMORBIDITY STUDY
102 Citations2002J. Broom, John Wilding +3 more
Orlistat weight loss is associated with improvements in cardiovascular co‐morbidities, and hence cardiovascular risk, and therefore cardiovascular risk in obese patients with cardiovascular risk.
Journal of HypertensionOrlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension
95 Citations2002George L. Bakris, David A. Calhoun +4 more
A weight-loss program with orlistat is more effective than diet alone to lower blood pressure and results in greater cardiovascular risk reduction.
…